Global | January 2026 — Pfizer Inc. advanced its post-pandemic transformation in 2025 through a series of targeted brand launches and label expansions across vaccines, oncology, rare diseases, and immunology. These launches reinforced Pfizer’s pivot toward high-value, science-driven therapeutics and are expected to materially influence its revenue mix, competitive positioning, and innovation strategy through 2026 and beyond.
Vaccines Portfolio: Respiratory Disease Prevention
ABRYSVO® — Respiratory Syncytial Virus (RSV)
Condition: RSV prevention in older adults and maternal immunization
In 2025, Pfizer scaled the global rollout of ABRYSVO, strengthening its leadership in the fast-growing RSV vaccine market. Expanded geographic adoption and broader physician awareness supported increasing uptake, particularly among aging populations and maternal health programs.
Strategic Impact:
RSV vaccines are positioned as a durable, seasonal revenue driver, with long-term potential driven by demographic trends and increasing public health prioritization of respiratory disease prevention.
Oncology Portfolio: Precision and Rare Cancers
ELREXFIO® — Multiple Myeloma
Condition: Relapsed or refractory multiple myeloma
Pfizer continued the commercial expansion of ELREXFIO, a bispecific antibody targeting BCMA and CD3, following regulatory milestones achieved earlier. In 2025, the focus shifted toward treatment sequencing, combination strategies, and real-world evidence generation.
Strategic Impact:
Bispecific antibodies represent a critical pillar of Pfizer’s oncology strategy, offering premium pricing, differentiated efficacy, and combination potential in hematologic malignancies.
BRAFTOVI® + MEKTOVI® — Targeted Solid Tumors
Condition: BRAF-mutated cancers, including melanoma and colorectal cancer
Label expansions and market optimization efforts in 2025 supported continued uptake of Pfizer’s targeted oncology combination therapies, particularly in biomarker-defined patient populations.
Strategic Impact:
Precision oncology assets enable Pfizer to maintain relevance in genomics-driven cancer care, supporting value-based reimbursement discussions.
Rare Disease Portfolio: High-Value Specialty Therapies
ZAVZPRET™ — Migraine
Condition: Acute migraine treatment
Following its recent approvals, ZAVZPRET gained commercial traction in 2025 as a needle-free, fast-acting migraine therapy, addressing unmet needs among patients who do not respond well to oral treatments.
Strategic Impact:
Neurology and rare disease brands offer strong margins and long product lifecycles, aligning with Pfizer’s goal to offset future patent expiries.
Immunology & Inflammation
VYNDAQEL® / VYNDAMAX® — Transthyretin Amyloid Cardiomyopathy
Condition: ATTR-CM
Pfizer sustained strong momentum for its amyloidosis franchise in 2025, supported by expanded diagnosis rates and physician education initiatives.
Strategic Impact:
Cardio-rare diseases remain a strategic anchor for Pfizer, combining specialty pricing with expanding patient identification through improved diagnostics.
Commercial & Digital Enablement
Across its 2025 launches, Pfizer increasingly deployed AI-driven commercial analytics, enabling:
- More precise physician targeting
- Improved demand forecasting
- Faster launch curve optimization
These capabilities are expected to shorten time-to-peak sales for upcoming brands entering the market in 2026.
Looking Ahead: 2026 and Beyond
Pfizer enters 2026 with:
- A more diversified revenue base
- Reduced reliance on pandemic-era products
- A stronger footprint in vaccines, oncology, rare disease, and specialty care
As additional lifecycle expansions and pipeline launches emerge, Pfizer’s 2025 brands are expected to serve as foundational growth engines, supporting sustained innovation investment and long-term competitiveness.
Conclusion
Pfizer’s 2025 launch strategy reflects a deliberate shift toward science-led brands addressing high-burden and high-value diseases. With strong commercial execution and continued pipeline advancement, these brands are positioned to play a decisive role in shaping Pfizer’s growth narrative through 2026 and the next decade.
By